{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T04:28:39Z","timestamp":1786508919156,"version":"build-2736575974"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":69,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Innovation Capability Support Program for Medical Research Projects of Xi'an Science and Technology Bureau","award":["23YXYJ0123"],"award-info":[{"award-number":["23YXYJ0123"]}]},{"name":"Hospital level Fund of the First Affiliated Hospital of Xi'an Medical University","award":["XYYFY-2023-08"],"award-info":[{"award-number":["XYYFY-2023-08"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-026-05344-y","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:43:37Z","timestamp":1780533817000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A bibliometric analysis of the research landscape of lenalidomide resistance in multiple myeloma"],"prefix":"10.1007","volume":"17","author":[{"given":"Ruihua","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingjuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuanghui","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinqian","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yani","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"key":"5344_CR1","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41572-024-00529-7","volume":"10","author":"F Malard","year":"2024","unstructured":"Malard F, Neri P, Bahlis NJ, Terpos E, Moukalled N, Hungria VTM, et al. Multiple myeloma. Nat Reviews Disease Primers. 2024;10:45.","journal-title":"Nat Reviews Disease Primers"},{"key":"5344_CR2","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1038\/s41598-024-83630-x","volume":"15","author":"Q Hou","year":"2025","unstructured":"Hou Q, Li X, Ma H, Fu D, Liao A. A systematic epidemiological trends analysis study in global burden of multiple myeloma and 29 years forecast. Sci Rep. 2025;15:2204.","journal-title":"Sci Rep"},{"key":"5344_CR3","first-page":"2516","volume":"111","author":"SK Kumar","year":"2008","unstructured":"Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood J Am Soc Hematol. 2008;111:2516\u201320.","journal-title":"Blood J Am Soc Hematol"},{"key":"5344_CR4","doi-asserted-by":"crossref","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A, Cancer statistics. 2023. CA: a cancer journal for clinicians. 2023;73:17\u201348.","DOI":"10.3322\/caac.21763"},{"key":"5344_CR5","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1002\/ajh.25791","volume":"95","author":"SV Rajkumar","year":"2020","unstructured":"Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol. 2020;95:548\u201367.","journal-title":"Am J Hematol"},{"key":"5344_CR6","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s41408-020-0273-x","volume":"10","author":"MA Dimopoulos","year":"2020","unstructured":"Dimopoulos MA, Jakubowiak AJ, McCarthy PL, Orlowski RZ, Attal M, Blad\u00e9 J, et al. Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma. Blood cancer J. 2020;10:17.","journal-title":"Blood cancer J"},{"key":"5344_CR7","first-page":"2366","volume":"126","author":"EC Fink","year":"2015","unstructured":"Fink EC, Ebert BL. The novel mechanism of lenalidomide activity. Blood J Am Soc Hematol. 2015;126:2366\u20139.","journal-title":"Blood J Am Soc Hematol"},{"key":"5344_CR8","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1200\/JCO.2017.72.6679","volume":"35","author":"PL McCarthy","year":"2017","unstructured":"McCarthy PL, Holstein SA, Petrucci MT, Richardson PG, Hulin C, Tosi P, et al. Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis. J Clin Oncol. 2017;35:3279\u201389.","journal-title":"J Clin Oncol"},{"key":"5344_CR9","doi-asserted-by":"publisher","first-page":"963","DOI":"10.3390\/cancers15030963","volume":"15","author":"P Kulig","year":"2023","unstructured":"Kulig P, Milczarek S, Bakinowska E, Szalewska L, Baumert B, Machali\u0144ski B. Lenalidomide in Multiple Myeloma: Review of Resistance Mechanisms, Current Treatment Strategies and Future Perspectives. Cancers. 2023;15:963.","journal-title":"Cancers"},{"key":"5344_CR10","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1182\/blood.2020007081","volume":"137","author":"S Gooding","year":"2021","unstructured":"Gooding S, Ansari-Pour N, Towfic F, Ortiz Est\u00e9vez M, Chamberlain PP, Tsai KT, et al. Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma. Blood. 2021;137:232\u20137.","journal-title":"Blood"},{"key":"5344_CR11","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.clml.2018.03.007","volume":"18","author":"A Dehghanifard","year":"2018","unstructured":"Dehghanifard A, Kaviani S, Abroun S, Mehdizadeh M, Saiedi S, Maali A, et al. Various signaling pathways in multiple myeloma cells and effects of treatment on these pathways. Clin Lymphoma Myeloma Leuk. 2018;18:311\u201320.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"5344_CR12","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1016\/S1470-2045(20)30756-7","volume":"22","author":"P Moreau","year":"2021","unstructured":"Moreau P, Kumar SK, San Miguel J, Davies F, Zamagni E, Bahlis N, et al. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. Lancet Oncol. 2021;22:e105\u201318.","journal-title":"Lancet Oncol"},{"key":"5344_CR13","doi-asserted-by":"publisher","first-page":"705033","DOI":"10.3389\/fped.2021.705033","volume":"9","author":"Q Zhou","year":"2021","unstructured":"Zhou Q, Kong H-B, He B-M, Zhou S-Y. Bibliometric analysis of bronchopulmonary dysplasia in extremely premature infants in the web of science database using CiteSpace software. Front Pead. 2021;9:705033.","journal-title":"Front Pead"},{"key":"5344_CR14","doi-asserted-by":"publisher","first-page":"1003228","DOI":"10.3389\/fphar.2022.1003228","volume":"13","author":"Z Hou","year":"2022","unstructured":"Hou Z, Jiang P, Su S, Zhou H. Hotspots and trends in multiple myeloma bone diseases: a bibliometric visualization analysis. Front Pharmacol. 2022;13:1003228.","journal-title":"Front Pharmacol"},{"key":"5344_CR15","doi-asserted-by":"publisher","first-page":"166","DOI":"10.3390\/foods9020166","volume":"9","author":"X-L Zhang","year":"2020","unstructured":"Zhang X-L, Zheng Y, Xia M-L, Wu Y-N, Liu X-J, Xie S-K, et al. Knowledge domain and emerging trends in vinegar research: a bibliometric review of the literature from WoSCC. Foods. 2020;9:166.","journal-title":"Foods"},{"key":"5344_CR16","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s11192-009-0146-3","volume":"84","author":"N Van Eck","year":"2010","unstructured":"Van Eck N, Waltman L. Software survey: VOSviewer, a computer program for bibliometric mapping. Scientometrics. 2010;84:523\u201338.","journal-title":"Scientometrics"},{"key":"5344_CR17","unstructured":"Synnestvedt MB, Chen C, Holmes JH, editors. CiteSpace II: visualization and knowledge discovery in bibliographic databases. AMIA annual symposium proceedings; 2005: American Medical Informatics Association."},{"key":"5344_CR18","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.joi.2017.08.007","volume":"11","author":"M Aria","year":"2017","unstructured":"Aria M, Cuccurullo C. bibliometrix: An R-tool for comprehensive science mapping analysis. J Informetrics. 2017;11:959\u201375.","journal-title":"J Informetrics"},{"key":"5344_CR19","doi-asserted-by":"crossref","unstructured":"Wang R, Lewis M, Zheng-Pywell R, Julson J, Smithson M, Chen H. Using the H-index as a factor in the promotion of surgical faculty. Heliyon. 2022;8.","DOI":"10.1016\/j.heliyon.2022.e09319"},{"key":"5344_CR20","doi-asserted-by":"crossref","unstructured":"Egghe L. Theory and practise of the g-index. 2006.","DOI":"10.1007\/s11192-006-0144-7"},{"key":"5344_CR21","first-page":"04023047","volume":"149","author":"ZP Ba\u017eant","year":"2023","unstructured":"Ba\u017eant ZP, Nguyen HT. Proposal of m-index for rating fracture and damage models by their ability to represent a set of distinctive experiments. J Eng Mech. 2023;149:04023047.","journal-title":"J Eng Mech"},{"key":"5344_CR22","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1001\/jama.295.1.90","volume":"295","author":"E Garfield","year":"2006","unstructured":"Garfield E. The history and meaning of the journal impact factor. JAMA. 2006;295:90\u20133.","journal-title":"JAMA"},{"key":"5344_CR23","doi-asserted-by":"publisher","first-page":"101494","DOI":"10.1016\/j.joi.2024.101494","volume":"18","author":"D Kosyakov","year":"2024","unstructured":"Kosyakov D, Pislyakov V. I\u2019d like to publish in Q1, but there\u2019s no Q1 to be found: Study of journal quartile distributions across subject categories and topics. J Informetrics. 2024;18:101494.","journal-title":"J Informetrics"},{"key":"5344_CR24","doi-asserted-by":"publisher","first-page":"921","DOI":"10.2147\/OTT.S398118","volume":"18","author":"N van de Donk","year":"2025","unstructured":"van de Donk N, Bahlis NJ, Pawlyn C, Gay F, Mateos MV, Weisel K, et al. The Role of CELMoD Agents in Multiple Myeloma. Onco Targets Ther. 2025;18:921\u201333.","journal-title":"Onco Targets Ther"},{"key":"5344_CR25","doi-asserted-by":"crossref","unstructured":"Geng C, Chen W, Zhu H-H. CAR-T therapy moving to first-line in multiple myeloma: latest updates from the 2025 ASH annual meeting. Journal of Hematology & Oncology. 2026;19:25.","DOI":"10.1186\/s13045-026-01793-8"},{"key":"5344_CR26","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau P, Garfall AL, van de Donk NW, Nahi H, San-Miguel JF, Oriol A, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022;387:495\u2013505.","journal-title":"N Engl J Med"},{"key":"5344_CR27","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1182\/blood-2024-205757","volume":"144","author":"A Zayad","year":"2024","unstructured":"Zayad A, Ahmed N, Mahmoudjafari Z, Skikne B, Lin TL, Mushtaq MU, et al. The Impact of Financial Support on the Development of Clinical Research in Multiple Myeloma: An in-Depth Analysis (1980\u20132024). Blood. 2024;144:2288.","journal-title":"Blood"},{"key":"5344_CR28","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","volume":"376","author":"M Attal","year":"2017","unstructured":"Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M, et al. Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma. N Engl J Med. 2017;376:1311\u201320.","journal-title":"N Engl J Med"},{"key":"5344_CR29","first-page":"679","volume":"116","author":"PG Richardson","year":"2010","unstructured":"Richardson PG, Weller E, Lonial S, Jakubowiak AJ, Jagannath S, Raje NS, et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood J Am Soc Hematol. 2010;116:679\u201386.","journal-title":"Blood J Am Soc Hematol"},{"key":"5344_CR30","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.6004\/jnccn.2023.0061","volume":"21","author":"SK Kumar","year":"2023","unstructured":"Kumar SK, Callander NS, Adekola K, Anderson LD Jr., Baljevic M, Baz R, et al. Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023;21:1281\u2013301.","journal-title":"J Natl Compr Canc Netw"},{"key":"5344_CR31","doi-asserted-by":"crossref","unstructured":"Chong PSY, Chng WJ, de Mel S. STAT3: A Promising Therapeutic Target in Multiple Myeloma. Cancers (Basel). 2019;11.","DOI":"10.3390\/cancers11050731"},{"key":"5344_CR32","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s43556-024-00188-w","volume":"5","author":"Q Lu","year":"2024","unstructured":"Lu Q, Yang D, Li H, Niu T, Tong A. Multiple myeloma: signaling pathways and targeted therapy. Mol Biomed. 2024;5:25.","journal-title":"Mol Biomed"},{"key":"5344_CR33","doi-asserted-by":"crossref","unstructured":"Kulig P, Milczarek S, Bakinowska E, Szalewska L, Baumert B, Machali\u0144ski B. Lenalidomide in Multiple Myeloma: Review of Resistance Mechanisms, Current Treatment Strategies and Future Perspectives. Cancers (Basel). 2023;15.","DOI":"10.3390\/cancers15030963"},{"key":"5344_CR34","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41408-019-0173-0","volume":"9","author":"YX Zhu","year":"2019","unstructured":"Zhu YX, Shi CX, Bruins LA, Wang X, Riggs DL, Porter B, et al. Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4. Blood Cancer J. 2019;9:19.","journal-title":"Blood Cancer J"},{"key":"5344_CR35","doi-asserted-by":"publisher","first-page":"e822","DOI":"10.1016\/S2352-3026(22)00290-3","volume":"9","author":"S Lonial","year":"2022","unstructured":"Lonial S, Popat R, Hulin C, Jagannath S, Oriol A, Richardson PG, et al. Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1\/2 trial. Lancet Haematol. 2022;9:e822\u201332.","journal-title":"Lancet Haematol"},{"key":"5344_CR36","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1056\/NEJMoa2303194","volume":"389","author":"PG Richardson","year":"2023","unstructured":"Richardson PG, Trudel S, Popat R, Mateos MV, Vangsted AJ, Ramasamy K, et al. Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2023;389:1009\u201322.","journal-title":"N Engl J Med"},{"key":"5344_CR37","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1080\/14656566.2021.1999411","volume":"23","author":"M Gavriatopoulou","year":"2022","unstructured":"Gavriatopoulou M, Malandrakis P, Ntanasis-Stathopoulos I, Dimopoulos MA. Nonselective proteasome inhibitors in multiple myeloma and future perspectives. Expert Opin Pharmacother. 2022;23:335\u201347.","journal-title":"Expert Opin Pharmacother"},{"key":"5344_CR38","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.4103\/0366-6999.156134","volume":"128","author":"SK Qiao","year":"2015","unstructured":"Qiao SK, Guo XN, Ren JH, Ren HY. Efficacy and Safety of Lenalidomide in the Treatment of Multiple Myeloma: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Chin Med J (Engl). 2015;128:1215\u201322.","journal-title":"Chin Med J (Engl)"},{"key":"5344_CR39","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1056\/NEJMoa1606038","volume":"375","author":"A Palumbo","year":"2016","unstructured":"Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, et al. Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2016;375:754\u201366.","journal-title":"N Engl J Med"},{"key":"5344_CR40","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1038\/s41375-020-01021-3","volume":"35","author":"M Dimopoulos","year":"2021","unstructured":"Dimopoulos M, Weisel K, Moreau P, Anderson LD Jr., White D, San-Miguel J, et al. Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse. Leukemia. 2021;35:1722\u201331.","journal-title":"Leukemia"},{"key":"5344_CR41","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1056\/NEJMoa1805762","volume":"379","author":"MA Dimopoulos","year":"2018","unstructured":"Dimopoulos MA, Dytfeld D, Grosicki S, Moreau P, Takezako N, Hori M, et al. Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma. N Engl J Med. 2018;379:1811\u201322.","journal-title":"N Engl J Med"},{"key":"5344_CR42","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41572-024-00529-7","volume":"10","author":"F Malard","year":"2024","unstructured":"Malard F, Neri P, Bahlis NJ, Terpos E, Moukalled N, Hungria VTM, et al. Multiple myeloma. Nat Rev Dis Primers. 2024;10:45.","journal-title":"Nat Rev Dis Primers"},{"key":"5344_CR43","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1182\/hematology.2020000109","volume":"2020","author":"N van de Donk","year":"2020","unstructured":"van de Donk N. Sequencing multiple myeloma therapies with and after antibody therapies. Hematol Am Soc Hematol Educ Program. 2020;2020:248\u201358.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"5344_CR44","doi-asserted-by":"crossref","unstructured":"Rocchi S, Zannetti BA, Marconi G, Lanza F. Multiple Myeloma: The Role of Autologous Stem Cell Transplantation in the Era of Immunotherapy. Cells. 2024;13.","DOI":"10.3390\/cells13100853"},{"key":"5344_CR45","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3324\/haematol.2021.278655","volume":"107","author":"A Kalff","year":"2022","unstructured":"Kalff A, Khong T, Ramachandran M, Ho PJ, Mollee P, D\u2019Rozario J, et al. Planned withdrawal of dexamethasone after pomalidomide low-dose dexamethasone induction for lenalidomide-refractory multiple myeloma (ALLG MM14). Haematologica. 2022;107:321\u20135.","journal-title":"Haematologica"},{"key":"5344_CR46","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1182\/blood.2022019531","volume":"142","author":"L Rosi\u00f1ol","year":"2023","unstructured":"Rosi\u00f1ol L, Oriol A, R\u00edos R, Blanchard MJ, Jarque I, Bargay J, et al. Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma. Blood. 2023;142:1518\u201328.","journal-title":"Blood"},{"key":"5344_CR47","doi-asserted-by":"publisher","first-page":"3616","DOI":"10.1182\/blood.2020008787","volume":"137","author":"T Facon","year":"2021","unstructured":"Facon T, Venner CP, Bahlis NJ, Offner F, White DJ, Karlin L, et al. Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma. Blood. 2021;137:3616\u201328.","journal-title":"Blood"},{"key":"5344_CR48","doi-asserted-by":"publisher","first-page":"4312","DOI":"10.1182\/blood-2022-157942","volume":"140","author":"L Vincent","year":"2022","unstructured":"Vincent L, Charvet-Rumpler A, Benboubker L, Calmettes C, Stoppa A-M, Laribi K, et al. Effectiveness and Safety of Ixazomib in Combination with Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma in a Real-Life Population in France: The Remix Study. Blood. 2022;140:4312\u20134.","journal-title":"Blood"},{"key":"5344_CR49","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/S1470-2045(21)00128-5","volume":"22","author":"MA Dimopoulos","year":"2021","unstructured":"Dimopoulos MA, Terpos E, Boccadoro M, Delimpasi S, Beksac M, Katodritou E, et al. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22:801\u201312.","journal-title":"Lancet Oncol"},{"key":"5344_CR50","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","volume":"29","author":"AM Lesokhin","year":"2023","unstructured":"Lesokhin AM, Tomasson MH, Arnulf B, Bahlis NJ, Miles Prince H, Niesvizky R, et al. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med. 2023;29:2259\u201367.","journal-title":"Nat Med"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-026-05344-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-05344-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-05344-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T03:49:33Z","timestamp":1786506573000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-026-05344-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,4]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5344"],"URL":"https:\/\/doi.org\/10.1007\/s12672-026-05344-y","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,4]]},"assertion":[{"value":"24 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1161"}}